Skip to main content
70°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ayala Pharmaceuticals
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 09, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
IMNM
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
IMNM
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
IMNM
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 06, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
August 01, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
November 17, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
AYLA
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
November 16, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
AYLA
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 04, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
AYLA
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
ADXS
AYLA
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
September 29, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Tickers
AYLA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.